$GSK Cashflow Statement | Understand Stock

$GSK

$51.10 +$0.35 (0.69%) Close

$GSK Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated cash flow statement

In millions of GBP, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flow from operating activities
Profit after taxation for the year from continuing operations
Total profit for the year
Adjustments reconciling profit after tax to operating cash flows
Cash generated from operations attributable to continuing operations
Cash generated from operations
Taxation paid
Net cash inflow/(outflow) from continuing operating activities
Cash generated from operations attributable to discontinued operations
Taxation paid from discontinued operations
Net operating cash flows attributable to discontinued operations
Total net cash inflow/(outflow) from operating activities
Cash flow from investing activities
Purchase of property, plant and equipment
Proceeds from sale of property, plant and equipment
Purchase of intangible assets
Proceeds from sale of intangible assets
Purchase of equity investments
Proceeds from sale of equity investments
Disposal of businesses, net of cash disposed
Share transactions with non-controlling interests
Purchase of businesses, net of cash acquired
Investments in associates and joint ventures
Proceeds from disposal of associates and joint ventures
Contingent consideration paid
Disposal of businesses
Interest received
(Increase)/decrease in liquid investments
Dividends from joint ventures and associates
Net cash inflow/(outflow) from continuing investing activities
Net investing cash flows attributable to discontinued operations
Dividend and distributions from investments
Total net cash inflow/(outflow) from investing activities

Cash flow from financing activities
Issue of share capital
Purchase of non-controlling interests
Repayment of long-term loans
Issue of long-term notes
Repayment of short-term loans
Net increase/(decrease) in short-term loans
Increase in other short-term loans
Repayment of other short-term loans
Repayment of lease liabilities
Interest paid
Dividends paid to shareholders
Purchase of treasury shares
Distribution to non-controlling interests
Contributions from non-controlling interests
Other financing items
Net cash inflow/(outflow) from continuing financing activities
Net financing cash flows attributable to discontinued operations
Total net cash inflow/(outflow) from financing activities

Increase/(decrease) in cash and bank overdrafts in the year
Cash and bank overdrafts at the end of the year
Cash and bank overdrafts at end of the year comprise:
Cash and cash equivalents
Cash and cash equivalents reported in assets held for sale
Cash and cash equivalents after assets held for sale reported
Bank overdrafts

Cash and bank overdrafts at the beginning of the year
Exchange adjustments

Comments